Controlled delivery of a new broad spectrum antibacterial agent against colitis: In vitro and in vivo performance

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 96, Issue , 2015, Pages 152-161

  Nieto Bobadilla, M S ^a,b   Siepmann, F ^a,b   Djouina, M ^a   Dubuquoy, L ^a   Tesse, N ^c   Willart, J F ^a   Dubreuil, L ^a   Siepmann, J ^a,b   Neut, C ^a  

^a UNIV LILLE   (France)

^b France   (France)

^c Septeos   (France)

Author keywords

Antibiotic; Coated pellet; Colitis; Controlled release; Mini tablet

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL ENZYME; BENZYL BENZOATE; CARYOPHYLLENE; CIN 102; CINEOLE; CINNAMYL ACETATE; LINALOOL; POLYMER; TRANS 2 METHOXYCINNAMALDEHYDE; TRANS CINNAMALDEHYDE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BENZOIC ACID DERIVATIVE; CIN-102; CINNAMIC ACID DERIVATIVE; DRUG COMBINATION; TABLET; TERPENE;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; BACTERIAL LOAD; COATED PELLET; COLITIS; COLON; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DIARRHEA; DISEASE COURSE; DRUG COATING; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG PELLET; DRUG SOLUBILITY; ENTERITIS; ENTEROBACTERIACEAE; FILM COATING; FLUIDIZED BED; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY BOWEL DISEASE; INTESTINE; INTESTINE MUCOSA; MALE; MINI TABLET; MOUSE; NONHUMAN; RECTUM HEMORRHAGE; SPHERONIZATION; TABLET; UPPER GASTROINTESTINAL TRACT; ANIMAL; C57BL MOUSE; CHEMISTRY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG COMBINATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG FORMULATION; DRUG RELEASE; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PROCEDURES; SOLUBILITY; SURFACE PROPERTY;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; BENZOATES; CALORIMETRY, DIFFERENTIAL SCANNING; CINNAMATES; COLITIS; COLON; DRUG COMBINATIONS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; MALE; MICE, INBRED C57BL; SOLUBILITY; SURFACE PROPERTIES; TABLETS; TERPENES;

EID: 84938832382     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2015.07.012     Document Type: Article

References (42)

1. S. Danese, and C. Fiocchi Etiopathogenesis of inflammatory bowel diseases World J. Gastroenterol. 12 2006 4807 4812
2. C. Fiocchi Inflammatory bowel disease pathogenesis: therapeutic implications Chin. J. Dig. Dis. 6 2005 6 9
3. T.T. MacDonald Breakdown of tolerance to the intestinal bacterial flora in inflammatory bowel disease (IBD) Clin. Exp. Immunol. 102 1995 445 447
4. T.T. Macdonald, and G. Monteleone Immunity, inflammation, and allergy in the gut Science 307 2005 1920 1925
5. G.P. Pineton de Chambrun, J. Torres, A. Darfeuille-Michaud, and J.-F. Colombel The role of anti(myco)bacterial interventions in the management of IBD: is there evidence at all? Dig. Dis. 30 2012 358 367
6. S.L. Wang, Z.R. Wang, and C.Q. Yang Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease Exp. Ther. Med. 4 2012 1051 1056
7. G.L. Arnold, M.R. Beaves, V.O. Pryjdun, and W.J. Mook Preliminary study of ciprofloxacin in active Crohn's disease Inflamm. Bowel Dis. 8 2002 10 15
8. P. Gionchetti, F. Rizzello, C. Morselli, R. Romagnoli, and M. Campieri Management of inflammatory bowel disease: does rifaximin offer any promise? Chemotherapy 51 2005 96 102
9. K. Bush, P. Courvalin, G. Dantas, J. Davies, B. Einstein, P. Huovinem, and et al. Tackling antibiotic resistance Nat. Rev. Micro. 9 2011 894 896
10. H.W. Boucher, G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert, L.B. Rice, and et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America Clin. Infect. Dis. 48 2009 1 12
11. J.M. Hughes Preserving the lifesaving power of antimicrobial agents JAMA 305 2011 1027 1028
12. N.S. Radulović, P.D. Blagojević, Z.Z. Stojanović-Radić, and N.M. Stojanović Antimicrobial plant metabolites: structural diversity and mechanism of action Curr. Med. Chem. 20 2013 932 952
13. H. Brötz-Oesterhelt, and N.A. Brunner How many modes of action should an antibiotic have? Curr. Opin. Pharmacol. 8 2008 564 573
14. F. Solórzano-Santos, and M.G. Miranda-Novales Essential oils from aromatic herbs as antimicrobial agents Curr. Opin. Biotechnol. 23 2012 136 141
15. J. Gertsch Botanical drugs, synergy, and network pharmacology: forth and back to intelligent mixtures Planta Med. 77 2011 1086 1098
16. A. Maroni, M.D. Del Curto, L. Zema, A. Foppoli, and A. Gazzaniga Film coatings for oral colon delivery Int. J. Pharm. 457 2013 372 394
17. P.J. Wilson, and A.W. Basit Exploiting gastrointestinal bacteria to target drugs to the colon: an in vitro study using amylose coated tablets Int. J. Pharm. 300 2005 89 94
18. Y. Karrout, C. Neut, C. Wils, F. Siepmann, L. Deremaux, L. Dubreuil, and et al. Colon targeting with bacteria-sensitive films adapted to the disease state Eur. J. Pharm. Biopharm. 73 2009 74 81
19. F.J.O. Varum, G.B. Hatton, A.C. Freire, and A.W. Basit A novel coating concept for ileo-colonic drug targeting: proof of concept in humans using scintigraphy Eur. J. Pharm. Biopharm. 84 2013 573 577
20. Y. Karrout, L. Dubuquoy, C. Piveteau, F. Siepmann, E. Moussa, D. Wils, T. Beghyn, C. Neut, M.-P. Flament, L. Guerin-Deremaux, L. Dubreuil, B. Deprez, P. Desreumaux, and J. Siepmann In vivo efficacy of microbiota-sensitive coatings for colon targeting: a promising tool for IBD therapy J. Control. Release 197 2015 121 130
21. L.F.A. Asghar, and S. Chandran Multiparticulate formulation approach to colon specific drug delivery: current perspectives J. Pharm. Pharmaceut. Sci. 9 2006 327 338
22. L. Vervoort, and R. Kinget In vitro degradation by colonic bacteria of inulinHP incorporated in Eudragit RS films Int. J. Pharm. 129 1996 185 190
23. C. Favier, C. Neut, C. Mizon, A. Cortot, J.F. Colombel, and J. Mizon Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease Dig. Dis. Sci. 42 1997 817 822
24. R. Bodmeier, and O. Paeratakul Process and formulation variables affecting the drug release from chlorpheniramine maleate-loaded beads coated with commercial and self-prepared aqueous ethyl cellulose pseudolatexes Int. J. Pharm. 70 1991 59 68
25. J. Siepmann, and F. Siepmann Mathematical modeling of drug dissolution Int. J. Pharm. 453 2013 12 24
26. F. Lecomte, J. Siepmann, M. Walther, R.J. MacRae, and R. Bodmeier Polymer blends used for the coating of multiparticulates: comparison of aqueous and organic coating techniques Pharm. Res. 21 2004 882 890
27. C. Lupp, M.L. Robertson, M.E. Wickham, I. Sekirov, O.L. Champion, E.C. Gaynor, and et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of enterobacteriaceae Cell Host Microbe 2 2007 119 129
28. G. Loh, and M. Blaut Role of commensal gut bacteria in inflammatory bowel diseases Gut Microbes 3 2012 544 555
29. P. Seksik, L. Rigottier-Gois, G. Gramet, M. Sutren, P. Pochart, P. Marteau, and et al. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon Gut 52 2003 237 242
30. E. Cario, and D.K. Podolsky Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease Infect. Immun. 68 2000 7010 7017
31. M.M. Heimesaat, A. Fischer, B. Siegmund, A. Kupz, J. Niebergall, D. Fuchs, and et al. Shift towards pro-inflammatory intestinal bacteria aggravates acute murine colitis via Toll-like receptors 2 and 4 PLoS ONE 2 2007 e662
32. D.N. Frank, A.L. St Amand, R.A. Feldman, E.C. Boedeker, N. Harpaz, and N.R. Pace Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases Proc. Natl. Acad. Sci. USA 104 2007 13780 13785
33. M. Baumgart, B. Dogan, M. Rishniw, G. Weitzman, B. Bosworth, R. Yantiss, and et al. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum ISME J. 1 2007 403 418
34. H.C. Rath, M. Schultz, R. Freitag, L.A. Dieleman, F. Li, H.J. Linde, and et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice Infect. Immun. 69 2001 2277 2285
35. K.L. Madsen, J.S. Doyle, M.M. Tavernini, L.D. Jewell, R.P. Rennie, and R.N. Fedorak Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice Gastroenterology 118 2000 1094 1105
36. S. Fiorucci, E. Distrutti, A. Mencarelli, M. Barbanti, E. Palazzini, and A. Morelli Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis Digestion 66 2002 246 256
37. C. Prantera, H. Lochs, M. Campieri, M.L. Scribano, G.C. Sturniolo, F. Castiglione, and et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin Aliment. Pharmacol. Ther. 23 2006 1117 1125
38. J.F. Colombel, M. Lémann, M. Cassagnou, Y. Bouhnik, B. Duclos, J.L. Dupas, and et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease Am. J. Gastroenterol. 94 1999 674 678
39. T. Ohkusa, K. Kato, S. Terao, T. Chiba, K. Mabe, K. Murakami, and et al. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial Am. J. Gastroenterol. 105 2010 1820 1829
40. C. Pannee, I. Chandhanee, and L. Wacharee Antiinflammatory effects of essential oil from the leaves of Cinnamomum cassia and cinnamaldehyde on lipopolysaccharide-stimulated J774A.1 cells J. Adv. Pharm. Technol. Res. 5 2014 164 170
41. K.A. Kuhn, N.A. Manieri, T.C. Liu, and T.S. Stappenbeck IL-6 stimulates intestinal epithelial proliferation and repair after injury PLoS ONE 9 2014 e114195
42. D.S. Shouval, J. Ouahed, A. Biswas, J.A. Goettel, B.H. Horwitz, C. Klein, and et al. Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans Adv. Immunol. 122 2014 177 210